From 2024 to 2028, the forecasted sales of antihypertensive medicine in Canada remain constant at 0.3% of total sales. No year-on-year changes are observed for this period. In 2023, antihypertensive medicine sales were also at 0.3%, indicating a stable market share across these years. Despite the lack of growth, this reflects a steady demand for antihypertensive medicines in the Canadian market.

Future trends to watch for include:

Potential shifts in market share due to new drug introductions or generic competition.
Changes in healthcare policies affecting prescription practices.
Demographic trends, such as an aging population, which may influence demand.

Download as XLS

More about Antihypertensive Industry 2025-2029